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ABSTRACT
Each year over 2 million women are given a breast cancer diagnosis and over half a million
women succumb to the disease yearly. As technology advances in the world of radiation
oncology, automated planning softwares, such as Radformation’s EZFluence, are being utilized
to streamline the treatment planning process. This study was designed to investigate whether the
automated plans are dosimetrically equivalent to traditionally planned 3D field in field tangential
plans. Is there a disadvantage to using these automated softwares? Three different dosimetrists
with varying backgrounds replanned 27 previously treated breast cancer patients and an
assortment of comparisons were ran between the new automated software plans and the
previously treated traditional plans. It was found that the automated software plans had better
whole breast coverage while reducing the higher range hot spots. The comparisons ran between
the three new planners showed that the less experienced dosimetrists were able to make
comparable, if not better, plans than the more experienced planner. The study found no
disadvantages to organ at risk dose or plan quality, so it could be concluded that adding an
automated planning software, such as EZFluence, to a radiation oncology department could help
staff create high quality breast treatment plans in a fraction of the time allowing time to focus
efforts in other areas.
Keywords: breast cancer, automated planning software, dosimetry, field in field
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INTRODUCTION
Automated planning softwares, such as EZFluence, have helped the 3D field in field
(FiF) breast treatment planning process become faster and more streamlined. Does automating
the method come at a risk to the patient’s threat of cardiac events and does the dosimetrist
designing the plan play a part in this risk? This study will take a quantitative look at breast
cancer plans and heart doses, specifically the left anterior descending artery (LAD) when
planned manually using field in field technique and planned automatically utilizing EZFluence
software. Multiple dosimetrists will be planning the same patients to allow for inter-dosimetrist
plan comparisons.
Breast Cancer Information
For the female population, breast cancer is the most common type of cancer in the world
with 1 in every 8 women developing the disease in their lifetime and over a half million deaths
worldwide each year from it (Brentnall et al., 2018). Multiple risk factors can contribute to the
likelihood of developing breast cancer ranging from lifestyle and environmental factors to
genetics (Momenimovahed & Salehiniya, 2019). Additionally, being overweight or obese, a
sedentary lifestyle and smoking all contribute to the chances of developing breast cancer; as do
alcohol consumption, smoking and a high fat diet. Environmental factors that may contribute to a
women’s risk level include air pollution (rural vs. metropolitan home) and socioeconomic status
in relation to a lack of screening and poor health choices in those with a lower status. Being
woman versus male inherently means that there is a higher chance of developing the disease
being that only 1% of breast cancer diagnoses are for male patients. Age is also a contributing
factor, as a person gets older, there is a greater chance of developing the disease. It is worth
mentioning, that frequently when breast cancer presents in younger women, the tumors are often
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large and more aggressive than what is typical in older women. Childbirth, or the lack thereof
and breastfeeding can also contribute to a women’s risk of developing the disease. Particularly,
an older age at first childbirth, or no childbirths at all and a lack of breastfeeding
(Momenimovahed & Salehiniya, 2019). A common theme in a lot of the risk factors for
developing breast cancer is that they typically involve a process that will affect the women’s
hormone levels, particularly estrogen, which can lead to the development of the disease.
Genetics play a large contributing role in whether a woman will develop breast cancer in her life
and what kind of breast cancer it will be. Family history is something that researchers pay close
attention to, having more than 2 immediate relatives develop the disease increases the patient’s
own odds dramatically. BRCA1 and BRCA2 are tumor suppressor genes present in all people,
they help prevent and fight cancer by preventing cells from reproducing too rapidly (Hereditary
Breast Cancer and BRCA Genes | Bring Your Brave | CDC). Women with BRCA1 and BRCA2
mutations, which are changes in the DNA makeup, are at a substantially higher risk of
developing the disease when compared to those who are not carriers. BRCA+ patients tend to
have a much higher likelihood of presenting with triple negative breast cancer, meaning that it
does not respond well to hormone therapy, making it more difficult to treat and cure than
hormone positive breast cancer (Peshkin et al., 2010).
Radiation Treatment Information
If the patient is deemed a candidate for radiation therapy, the first step in that process
would be an initial consultation with the radiation oncologist, a physician who specializes in the
treatment and care of radiation patients, and a nurse who specializes in the same field. After the
consultation and an consent to proceed with treatment, the patient would be set up for a CT
simulation. During this process, the patient’s breast or chest wall is marked by the physician to
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delineate breast tissue borders and the patient is positioned with either the effected side arm or
both arms raised above her head on a device known as a breast board. A computerized
tomography (CT) scan is performed of the area and transferred to treatment planning computers
where the physician can delineate treatment borders including a gross tumor volume (GTV),
disease which can be seen, palpated or imaged. The next volume that the radiation oncologist
will delineate is the clinical target volume (CTV) which includes the GTV and a margin for
subclinical disease which cannot be imaged. Finally, a planning target volume (PTV)
encompasses the GTV and the CTV and accounts for uncertainties that may arise from planning
techniques or patient setup techniques (Burnet, et al). Utilizing these volumes, a medical
dosimetrist can create a proper radiation plan to adequately treat the affected area. After the plan
has been approved by the physician, a medical physicist will do a quality assurance check on the
plan and it will then be ready to be delivered to the patient, this process commonly takes around
1-2 weeks. Prior to treatment approval by the radiation oncologist, there are a variety of dose
constraints that are commonly evaluated and must be met by the dosimetrist creating the plan.
Depending on patient positioning, breast size, tumor location and a variety of other factors, these
constraints can prove challenging to meet in some cases.
Radiation Dose Constraint Information
Multiple studies have shown that the risk of acute and long-term pulmonary side effects are
correlated with the amount of lung volume that is incidentally irradiated while treating a patient’s
breast cancer (Kimsey et al., 1994). A radiation dose of 20Gray (Gy), which can also be referred
to as the V20, the volume of lung tissue receiving 20Gy or 2000cGy, has been shown to be a
cutoff dose and going above this leads to a risk of developing pulmonary issues (Blom Goldman
et al., 2014). The heart is another critical organ that must be monitored closely when developing
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a radiation plan so that the dose can be minimized accordingly. Studies have found that there is a
relationship between patients receiving radiation therapy and a later development of cardiac
disease, a cutoff dose and treated volume are still topics of debate, but as with all radiation
practices, the ALARA concept of maintaining a dose “as low as reasonably achievable” is going
to provide the most benefit to the patient (Development and Validation of a Heart Atlas to Study
Cardiac Exposure to Radiation Following Treatment for Breast Cancer - PubMed, n.d.). One
study found that for every 1 Gray or 1000cGy in mean heart dose received, there is a 4-16%
relative increase in heart disease or major coronary events (Schlaak et al., 2020). A large factor
in the lack of consistent information and guidelines for heart constraints is a wide margin of
inconsistency in contouring the heart and its structures, therefore, a sizeable study was done to
create a heart contouring atlas which would provide step by step details, explanations and
pictures for the medical professionals contouring the heart to streamline the process and give the
radiation oncology community better data to mimic (Development and Validation of a Heart
Atlas to Study Cardiac Exposure to Radiation Following Treatment for Breast Cancer - PubMed,
n.d.). Along with the entire heart structure itself, the left anterior descending artery has also been
examined in detail as it is believed that this artery itself may be responsible for some of the
cardiac toxicity breast patients are developing after treatment has been completed. The volume of
the left anterior descending artery receiving 15Gy or 1500cGy, V15, has proven to be predictive
of the development of a major adverse cardiac event (Atkins et al, 2021). It is also thought that
the volume this artery is receiving may outweigh all other heart metrics, including mean heart
dose in terms of cardiac event risk (Atkins). For the breast tissue itself, skin reactions of some
sort are the most common side effect of radiation therapy with upward of 90% of patients seeing
a reaction. Erythema, reddening of the outer layer of skin, can be seen within hours of radiation
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treatment and is normally not symptomatic. When doses start to reach the 20-25Gy or 20002500cGy mark, a second skin reaction known as hyperemia will start to appear. This occurs
when the basal cell layer is damaged, and cells can’t reproduce quick enough to fix the
destruction. Dry desquamation, which is characterized by flaky, peeling skin, will start to occur
at doses above 40Gy or 4000cGy. Following erythema, hyperemia and dry desquamation, moist
desquamation starts to occur at doses between 45-50Gy or 4500-5000cGy. It is critical that the
physician and radiation team are aware of these side effects, moist desquamation that is treated
above 60Gy or 6000cGy can lead to infection, ulceration and radiation induced necrosis. There
are topical medications to help relieve the itch and pain from these side effects and they typically
clear up within 3-4 weeks after the completion of treatment. Fibrosis, a permanent, late occurring
effect, is thickening of the skin of the breast and when it reaches a high enough grade, it can be
debilitating and limit range of motion in the effected side. Fibrosis can occur when radiation
doses reach between 55-60Gy or 5500-6000cGy (White & Joiner, 2006). The side effects and
treatment risks previously mentioned are only a small sample of what a cancer patient might
endure while muddling through the grueling medical battle aimed at saving their lives.
Radiation Treatment Planning Software Information
For this reason and more, research is being done daily to try and automate and improve
the radiation therapy planning procedure to spare these patients of negative side effects and keep
doses to their normal, healthy tissue as low as possible. Automated planning systems, such as
EZFluence, created by the company Radformation (EZFluence), can make field in field (FiF)
planning as quick and simple as literally clicking a button. Studies have shown that it can reduce
planning time, improve the conformity index (CI), and provide a superior dose homogeneity
index (HI) than manually planned field in field plans (Benayun et al., 2020) For reference, the
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conformity index is defined as a CI equal to 1 corresponds to the ideal dose coverage, a CI
greater than 1 indicates that the irradiated volume exceeds the target volume, while a CI less than
one indicates that irradiated volume is missing target volume (Petrova et al., 2017). The
homogeneity index is a ratio between the maximum dose in the target volume and the reference
isodose line. An ideal HI is 1, and as the plan becomes less homogenous, the HI increases
(Petrova et al., 2017). Another study by Dragojević, et al., found that the D95% to the target
breast volume was better on every breast in the study using EZFluence as compared to the
original plans and the MU were significantly lower with the EZFluence plans (2021). This
coincides with Benyayun, et al. findings that homogeneity index is superior for the plans created
using automated software. EZFluence software delivers automated 3D treatment planning in just
the click of a button. It has revolutionized and streamlined the treatment planning process and
reduced the amount of time dosimetrists are spending to make conformal, homogenous plans by
84.6% (Yoder et al., 2019).
Radformation has another up-and-coming software that can simplify the radiation planning
process, ClearCheck (ClearCheck), an automated dose constraint monitoring software that is
now being used by many cancer sites across the world. ClearCheck allows for an automatic plan
evaluation in the click of a mouse. Radiation oncologists, physicists and other staff members in
the radiation department can create their own ClearCheck templates based on dose constraints
that should be met or certain treatment protocols that they are following. From there, attaching
your plan to the ClearCheck allows you to see real time values on the doses of importance, your
prescription and possible machine collision warnings. In the same fashion that EZFluence
streamlines the planning portion of a breast treatment, ClearCheck can streamline the evaluation
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process and make it very clear which dose constraints the dosimetrist is meeting, and which need
work (Sysock, n.d.).
By this point, it should be evident that multiple factors go into how a radiation oncologist
delineates a good breast treatment plan from a great breast treatment plan. The V20 of the lung,
mean heart dose/dose to the LAD, maximum hot spot and hot spot location are a few of these
factors. Every dosimetrist has their own way of planning, much like an art, no two are ever the
same. Some of this comes from how they were taught, where they studied, what planning
systems they use, and some is strictly knowledge based off years of experience. With EZFluence
software, is it possible that rookie dosimetrists could potentially create equivalent plans to
dosimetry veterans thanks to the help of their automated technology?
Study Information
This will be a retrospective study consisting of 27 patients who were previously planned and
treated using a traditional 3D tangential radiation plan. These patients were all planned by a
single dosimetrist utilizing the ClearCheck guidelines that were set forth for him. Following the
completion of their treatment, these patients were selected, and contoured by the same radiation
oncologist according to RTOG guidelines. The basis of the study will be to have three different
dosimetrists, all with varying degrees of experience, plan the patients utilizing the EZFluence
software and the same ClearCheck guidelines as the original dosimetrist had to follow. There
will also be a new ClearCheck running in the background that will look at dose constraints that
were not previously examined during the initial planning process. All patients will be planned
with a hypofractionated prescription of 266cGy a day for 16 treatments to a total dose of
4256cGy. No boost plans will be utilized or studied.
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Given the sample that is available to us, the study will include 27 patients for interdosimetrist FiF vs EZFluence comparison and 81 patient plans to compare to the original
dosimetrists FiF plan. Breast PTV or PTV_WB_EVA_dos (same thing) will be target of interest
for planning. A ClearCheck called “breast” will be used and is already in the system from
original plan generation, these are the constraints the original dosimetrist had to meet with his
plan. Target coverage goal was V4044cGy>95% (ideal) - 93% (acceptable). 6MV, 16MV or a
combination of the two energies may be utilized as this was an option for the original
dosimetrist. 107% or less should be goal for max point dose.
For comparing the three dosimetrists’ plans, a variety of dose constraints that are being
tracked will be looked at. An effort will be made to determine if there is statistical significance
between the dosimetrist experience level and the results of the dose constraints derived from
each individual plan. The D95% of the breast, V20Gy of the lung, dose to the LAD, CI and HI
will all be compared. Companies around the world are currently struggling to fill open job
positions and radiation oncology departments are not exempt from this issue. Having a software
available that might allow less experienced dosimetrists to create proficient treatment plans
quickly and effectively could prove beneficial for the hospital and the patient.

METHODOLOGY
Patient Selection
This is a retrospective study of 27 early-stage breast cancer patients who were previously
planned and treated at Robert Packer Hospital. A minimal risk IRB request was submitted and
approved by the Robert Packer Hospital and subsequently Grand Valley State University’s ethics
committee. All parties involved in the study completed required CITI training and proper
measures were taken to ensure patient confidentiality was maintained. The patient’s studies were
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taken and replanned by dosimetrists with varying degrees of experience to complete a dosimetric
analysis regarding whether utilizing EZFluence instead of traditional 3D field in field (FiF)
planning led to higher doses to organs at risk in the treatment area. The data will also be utilized
to assess whether EZFluence software can aid less experienced planners in creating equivalent
plans to veterans of the field. With the help of EZFluence and ClearCheck software’s, the
planners had a small set of constraints that they tried to meet based off a ClearCheck that was
utilized when the software was first put into effect in our cancer treatment center.
The 27 patients in this study, 16 left sided breast and 11 right sided breast, were all being
treated for breast cancer at our facility when ClearCheck software was first purchased for our
utilization. The patients were prescribed a hypofractionated treatment regimen of 266cGy daily
for 16 treatments to a total dose of 4256cGy. Even if the original prescription called for a boost,
it was ignored for this study. The planner was left to their own discretion regarding whether to
use 6x, 16x or a combination of both. The breasts were all planned as FiF treatments and within
the EZFluence software, the maximum number of segments is set at 5 with the minimum number
of monitor units (MU) set to 8. These guidelines were set by our radiation physicist when the
software was installed and for the purpose of continuity in the study, the numbers weren’t
adjusted while replanning the patients.
Planning Information
All patients were simulated using a GE Lightspeed simulator and no oral or intravenous
contrast was utilized. Radiopaque bb’s were placed at the superior and inferior margins of breast
tissue and radiopaque wire was used to delineate the lateral breast tissue margin as well as
patient midline. Following simulation, the patients were imported into the same treatment
planning system, Eclipse version 15.6 (Varian Eclipse). Using the contouring menu in ARIA
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version 15.1 (ARIA), the patients were all contoured by the same radiation oncologist, and he
utilized RTOG breast atlas guidelines to do so. The organs at risk contoured for the purpose of
this study included the contralateral breast, heart, left anterior descending (LAD) vessels and
both the ipsilateral and contralateral lungs.
All 27 patients were originally planned by the same dosimetrist, his ClearCheck was very
condensed, and the plans were created with manual FiF technique rather than with automated
software. He was aiming to obtain 95% coverage to 95%(ideal)-93%(acceptable) of the PTV
with a max dose of 110%. The V105% should have been kept below 10%.
For replanning the patients, the dynamic multileaf collimation (MLC) that was used for
the original plan was copied and pasted by using the insert new block tool in Eclipse external
beam planning. The pencil tool was used to draw the shape of the original MLC field and then it
was converted into MLC’s, this new plan, without any subfields, was the new base plan. For
continuity, the new planners all used this as their primary plan and proceeded to use EZFluence
to create their own FiF plan from there. This took out any random errors that may have occurred
from all three new planners creating the new treatment fields on their own.
Planner Experience
The planners being compared all have varying degrees of experience in the field of
radiation oncology. They will be presented here in order of decreasing experience. The most
experienced planner has a Master of Science degree in physics and is a board-certified physicist.
He has been a certified medical dosimetrist (CMD) for 24 years, this will be planner A. The
original dosimetrist has a Bachelor of Science in physics and has been a CMD for 13 years. The
next planner has a Bachelor of Science in applied health studies and has been a certified radiation
therapist for 11 years. She is currently enrolled in Grand Valley State University’s Master of
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Medical Dosimetry program and is set to graduate in August 2022, this will be planner B. The
final planner has a Bachelor of Science in biology and has been a certified radiation therapist for
2 years. She is currently enrolled in John Patrick University’s Master of Medical Dosimetry
program and is set to graduate in April 2022, this will be planner C.

Data Analysis
After replanning was complete, the ClearCheck data from all four planners were exported
into a Microsoft Excel Spread sheet. The data is separated by patient and planner and by side
effected, left breast or right breast. Dosimetric constraints of interest include The V100%,
V103%, V105% and V95%>95-93% for the target breast. The V100% of the lumpectomy cavity
for the GTV and PTV were also of interest. Other dose constraints that were reviewed include a
conformity index (CI100%) of 1.2-1.5, homogeneity index (HI) of 1, V20<15-20% for the
ipsilateral lung, mean heart dose<100cGy and a left anterior descending artery (LAD) mean
dose. For the hotspot in the plan, a number that should be kept as low as reasonably achievable,
the V103%, V105% and V107% were all reviewed.
Data comparisons were first computed between the original planner and an average result
of the other three planners combined. This allowed for an evaluation between the original 3D
planning technique and the EZFluence planning technique. Following this comparison, a
separate average and median were calculated for each dose constraint of interest for each of the
three new planners. The same average and median was calculated for the original planner, all of
this was done utilizing Microsoft Excel. Using these average and median results allowed a
comparison between the original planner and each individual planner to assess for any gross
differences in dose constraints across the plan. A manual count was performed for each planner,
each patient, regarding who met or surpassed the dose constraint (good), passed the dose
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constraint (acceptable), or didn’t pass the dose constraint (not acceptable). Counting these
numbers then allowed for statistical comparison regarding which planner or planners may have
done better or worse with the plan according to meeting dose constraints.

Results
A total of 27 early-stage breast cancer patients were replanned by three dosimetrists
utilizing automated planning software, EZFluence. Several two-tailed t-test were ran with SAS
software to compare the original 3D treatment plans to the new EZFluence plans (SAS Institute
Inc. SAS® OnDemand for Academics: Studio.; 2022). The V100% for the target breast was
found to be better for the automated planning software plans, 84.2% coverage, in comparison to
the standard 3D plans which averaged 79.1% coverage with a statistically significant p-value of
<0.0001 (Figure 1). The V103% was found to be statistically significant, p-value <0.0001, but in
favor of the traditional 3D planning technique. The EZFluence plans had an average V103% of
47.3% while the 3D plans had an average of 36.5% (Table 1). The V105% went back the other
direction to favor the EZFluence plans, p-value <0.005. The EZFluence plans had an average
V105% of 4.5% while the 3D plans V105% averaged 6.2%. The final constraint of interest for
the whole breast volume, V95%>95%-93% showed statistical significance in favor of the
EZFluence plans, p-value<0.001. However, with the EZFluence plans V95%>95%-93%
averaging 95.2% and the 3D plans V95%>95%-93% averaging 94.6%, clinical significance was
not found. A conformity index of the whole breast, CI100%, was also compared and found to be
statistically significant in favor of the 3D plans with a p-value of <0.0001. The EZFluence plans
averaged a CI100% of 1.39 while the 3D plans averaged 1.26. The homogeneity index, HI, was
found to be statistically significant with a p-value of <0.0001 in favor of the EZFluence plans.
With the EZFluence plans averaging an HI of 0.14 and the 3D plans averaging an HI of 0.15, the
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finding was not clinically significant. Moving on to the V100% of the lumpectomy cavity,
statistical significance with a p-value of <0.0130 was found in favor of the EZFluence plans. The
EZFluence plans had on average 90.3% coverage of the lumpectomy cavity while the traditional
3D plans averaged 85.6% coverage (Figure 2). For the lungs, a V16% of the ipsilateral side was
compared, V16% is looked at with hypofractionated breast plans rather than the V20% because
of the dosing differences, and there was statistical significance in favor of the EZFluence plans
with a p-value of 0.0206. Clinical significance was not found with the EZFluence plans V16%
averaging 8.76% and the 3D plans V16% averaging 8.84% (Table 1). Neither the mean heart
dose or mean LAD dose showed any statistical significance in their comparisons. When
comparing the plan hotspots, the V103% was found to be statistically significant with a p-value
of <0.0001 in favor of the 3D plans. On average, the EZFluence plans had a V103% of 653.3ccs
while the 3D plans average V103% was 488.4ccs. The V105% hotspot comparison showed no
statistical significance, however, the V107% hotspot was statistically significant in favor of the
EZFluence plans with a p-value of 0.0037. The EZFluence plans V107% was on average 1.1ccs
while the 3D plans averaged 3.8ccs (Table 1).
A second comparison of chi-square test were done using Microsoft Excel. All dose
constraints were looked at for the original 3D plans versus the EZFluence plans and the number
of times each constraint was found to be unacceptable, less than ideal, acceptable, and ideal. The
V95% of the whole breast was found to be statistically significant with a chi-square value of
0.0541 in favor of the EZFluence plans. The automated plans met this constraint ideally 48.2%
of the time while the 3D plans averaged 29.6% The V100% of the lumpectomy cavity showed a
statistical significance of 0.0351 in favor of the EZFluence plans. The V100% constraint for the
EZFluence plans was met ideally 29.6% of the time, while the 3D plans met the constraint
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ideally 11.1% of the time. Lastly, the V107% hotspot showed statistical significance with a chisquare value of 0 also in favor of the EZFluence plans. The EZFluence plans on average met the
V107% hotspots constraint on 88.9% of plans while the 3D V107% hotspot constraint was met
ideally just 51.9% of the time. None of the constraints for the unacceptable versus acceptable
comparisons showed any statistical significance.
The same set of comparisons were ran using repeated ANOVA and post-hoc paired
samples t-tests between the three replanning dosimetrists in an effort to evaluate if years of
experience played a part in quality of EZFluence plans produced. For V100% of the whole
breast, statistical significance was found with a p-value of 0.0061 in favor of planner A when
compared to planner B (Table 2). Both the V103% and V105% to the whole breast also showed
statistical significance with p-values of 0.0055 and 0.0063, respectively, and were in favor of
planner B over planner A (Table 2, Figure 3). No clinical significance was found between the
three planners regarding the V107% whole breast dose. The min D0.03cc constraint showed
statistical significance in favor of planner C, p-values both <0.0001, when comparing planners A
and C and planners B and C. The CI100% was also statistically significant, p-values of 0.0126
and 0.0383 respectively, between planners A and B and planners A and C. The less experienced
planners were in favor here, planner B and planner C respectively. Planner A was able to achieve
better coverage to the lumpectomy bed than planner B, V100%>95%, p-value 0.0203. The
V103% cc to the body was statistically significant, p-value 0.0079, in favor of planner B when
compared to planner A (Table 2). The V107% cc to the body was statistically significant, p-value
0.0007, in favor of planner C when compared to planner A (Table 2). Lastly, the body max dose
<110% constraint was statistically significant, p-values both <0.0001, in favor of planner C when
comparing planners A and C and planners B and C (Figure 4).
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Discussion
The purpose of this study was to explore whether EZFluence automatic planning software
could provide equivalent, if not better, organ at risk dose for breast plans compared to traditional
3D planning, but also whether it could allow less experienced dosimetrists to create plans that
were comparable to a more experienced dosimetrists plans. Of note, multiple studies on the
effects of radiation on the heart and left anterior descending artery have shown an increase in
post radiation therapy cardiac events (Atkins et al, 2021). Based on the information gathered in
this study, both the heart constraints and LAD constraints that showed any statistical significance
were all in favor of the traditional 3D plans, however, the difference in numbers were so small
that it was determined that no real clinical significance between the two types of plans existed. It
would be of benefit to the radiation oncology community to further research this topic as more
and more data is proving the dangers of dose to the cardiac structures and LAD vessel. One idea
could be that Radformation should provide more detailed training for utilizing their software so
that all users are producing the best plans with it that they can. The same was found to be true for
contralateral breast dose, the difference in numbers for this study was too small to be considered
clinically significant, but these constraints did show to be in favor of the EZFluence plans. Only
one of the six lung constraints that were compared showed any statistical significance and the
difference was too small to be considered clinically significant, but like the contralateral breast
dose, the numbers did fall in favor of the EZFluence plans. It would be difficult to draw a
conclusion about organ at risk dose benefits with EZFluence based on the results of this study for
the simple fact that there was little significant clinical differences to base these opinions on.
Equivalent organ at risk doses to the traditional plans could still be considered a win when
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accounting for the fact that the EZFluence plans are much quicker to create and the user-friendly
software is convenient for inexperienced planners. The same holds true for further research into
this topic as well, it could be that the patient anatomy utilized in this study didn’t see benefit
from the EZFluence plans vs the traditional 3D plans or it could be that the planners in the study
did not use the software to its fullest capacity.
Unlike the organ at risk results, the study did show that the EZFluence plans did a better
job at PTV whole breast and PTV lumpectomy bed coverage than the 3D plans did while at the
same time improving on the higher range hotspots, 105-107%. This is an ideal combination as
the plans were able to achieve good breast coverage while reducing the chances of severe skin
reactions in the patients. The chi-square comparisons ran to look at acceptable and ideal
constraint criteria showed favor toward the EZFluence plans. Coverage of the breast,
lumpectomy bed and limiting of the V107% hotspot were all achieved more for the EZFluence
plans than the 3D plans which is again, an ideal combination, any time that dosimetrists are able
to maximize tumor control probability while at the same time minimizing normal tissue
complication probability, it is considered a successful treatment plan.
For the comparison between level of experience and the quality of plans produced, there
was statistical evidence in favor of the less experienced dosimetrists creating equivalent if not
superior plans to the more experienced planner. One theory for this may be that the technology
has been part of their training process from the beginning whereas the elder dosimetrists learned
to plan while utilizing older treatment techniques and had to be trained on the use of
EZFluence’s software. Further research should be done to compare training processes and
planning techniques because it was evident when one planner excelled at controlling a certain
dose spread or lumpectomy bed coverage in comparison to the others. The world of radiation
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oncology is all in this fight together, to improve the quality of plans our patients are receiving, so
access to further education and planning techniques with these up-and-coming treatment
planning software’s is critical.

Conclusion
It could be noted that there was a lot of back and forth in the results section between the
EZFluence plans and the 3D plans. The EZFluence software helped achieve greater breast
coverage and lumpectomy bed coverage when looking at the V100% of both when compared to
the 3D plans (Figure 1). The traditional 3D plans were superior at keeping the lower range
hotspots, V103% and V105%, under control while the EZFluence plans did better at controlling
the higher range V107% hotspot (Table 1).
Radformation has stated that their software helps dosimetrists create plans with superior
CI and HI values, this was not found to be relevant in this study with the 3D plans having a
better CI value and the HI value being found to be clinically insignificant. There was also no
clinically meaningful difference for ipsilateral lung, heart, or LAD constraints between the two
planning techniques. As technology continues to advance in this field, more research should be
done on the possible benefits of automated planning software on plan conformality and organ at
risk doses.
Deciding between the use of traditional 3D treatment planning versus automated
EZFluence planning should be a department wide conversation based around the positives and
negatives of each technique and which dose constraints take precedence in the eyes of the
radiation oncologist. During these unprecedented times, having a software available that would
allow for less experienced planners to make high quality treatment plans could be a very
valuable resource.
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Table 1: Comparison of dose constraint goal vs. percent of coverage achieved for
EZFluence and 3D FiF plans

Whole Breast V100% Coverage
100.00%

Percent Coverage

95.00%
90.00%
EZFluence
85.00%
3D FiF
80.00%
75.00%
70.00%

Figure 1: Comparison of EZFluence plans whole breast coverage vs. 3D FiF plans whole
breast coverage
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PTV Lumpectomy Bed Coverage
100.00%
95.00%

Percent Coverage

90.00%
85.00%
EZFluence

80.00%

3D FiF
75.00%
70.00%
65.00%
60.00%

Figure 2: Comparison of lumpectomy bed coverage between EZFluence and 3D FiF plans
Structure
PTV Whole Breast
PTV Whole Breast

Constraint
V100%
V103%

Goal
%
%

Planner A
85.32%
51.84%

Planner B
83.39%
42.03%

Planner C
83.97%
48.04%

PTV Whole Breast

V105% ≤

10-15%

5.74%

4.05%

3.60%

PTV Lumpectomy Cavity
Hotspot
Hotspot
Ipsilateral Lung

V100% ≥
V103%
V107%≤
V1600cGy≤

95%
cc
2-10cc
10-15%

91.59%
711.82
1.55
0.0876

89.33%
613.88
1.64
0.0877

89.91%
634.27
0.10
0.0875

Table 2: Inter-dosimetrist comparison results for key dosimetric constraints
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Figure 3: Comparison of V105% hotspot coverage between the three replanning
dosimetrists

Figure 4: Comparison of body max dose between the three replanning dosimetrists
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